Your browser doesn't support javascript.
loading
Financial incentives to promote personalized medicine in Europe: an overview and guidance for implementation.
Koleva-Kolarova, Rositsa; Szilberhorn, László; Zelei, Tamás; Vellekoop, Heleen; Nagy, Balázs; Huygens, Simone; Versteegh, Matthijs; Mölken, Maureen Rutten-van; Wordsworth, Sarah; Tsiachristas, Apostolos.
Afiliación
  • Koleva-Kolarova R; Health Economics Research Centre, University of Oxford, Oxford, UK.
  • Szilberhorn L; Syreon Research Institute, Budapest, Hungary.
  • Zelei T; Faculty of Social Sciences, Eötvös Loránd University, Budapest, Hungary.
  • Vellekoop H; Syreon Research Institute, Budapest, Hungary.
  • Nagy B; Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands.
  • Huygens S; Syreon Research Institute, Budapest, Hungary.
  • Versteegh M; Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands.
  • Mölken MR; Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands.
  • Wordsworth S; Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands.
  • Tsiachristas A; Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.
Per Med ; 20(4): 305-319, 2023 07.
Article en En | MEDLINE | ID: mdl-37623911
ABSTRACT
The implementation of adequate financing and reimbursement of personalized medicine (PM) in Europe is still turbulent. The views and experience of stakeholders about barriers in financing and reimbursing PM and potential solutions were elicited and supplemented with literature findings to draft a set of recommendations. Key recommendations to overcome the barriers for adequately financing and reimbursing PM in different healthcare systems in Europe included the provision of legal foundations and establishment of large pan-European databases, use of financial-based agreements and regulation of transparency of prices and reimbursement, and creating a business-friendly environment and attractive market for innovation. The recommendations could be used by health authorities for designing a sequence of policy steps to ensure the timely access to beneficial PM.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Medicina de Precisión / Motivación Tipo de estudio: Guideline / Health_economic_evaluation / Prognostic_studies Aspecto: Implementation_research Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Per Med Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Medicina de Precisión / Motivación Tipo de estudio: Guideline / Health_economic_evaluation / Prognostic_studies Aspecto: Implementation_research Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Per Med Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido